-
Mashup Score: 88AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB) - 4 month(s) ago
/PRNewswire/ — Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company’s supplemental New…
Source: www.prnewswire.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 71
Immune checkpoint inhibitor (ICI) consolidation following concurrent chemoradiotherapy (CRT) substantially improved PFS and OS in the PACIFIC trial becoming the standard of care in locally-advanced, unresectable NSCLC. KRAS mutation may influence response to ICI.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 46Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program - 5 month(s) ago
Kirsten rat sarcoma (KRAS) viral oncogene mutations have been detected in about one third of non-small cell lung cancer (NSCLC) (39% non-squamous vs 4% squamous histology), with p.G12C being the most common pathogenic variant, reported in 12% of overall NSCLC and 39% of KRAS-mutant patients, respectively [1]. Differently from other oncogenic drivers (e.g EGFR, ALK, ROS1), KRASp.G12C mutations are more common in Caucasian and smoker populations [2,3], and are generally characterized by high levels of both programmed death ligand-1 (PD-L1) and tumor mutational burden (TMB) [4].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13One mutation to rule them all: Mutant KRAS controls tumor intrinsic and microenvironment signaling. - 5 month(s) ago
Abstract. In a recent study published in Cancer Discovery, Hsu and colleagues employ an elegant combination of single-cell and bulk RNA-seq experiments from mouse and human colorectal cancer (CRC) samples, patient-derived organoids, 2D in vitro systems, and in vivo validation in genetically engineered CRC mouse models to investigate how mutant KRAS (KRAS*) impacts the tumor microenvironment. They identify a molecular signaling cascade downstream of KRAS* that activates a specific program of lipid-rich CAFs, promoting tumor angiogenesis and progression. These findings may lead to new therapeutic strategies for CRC patients with KRAS*.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Brief report on the efficacy of sotorasib in KRAS-Mutated NSCLC patients with brain metastases - 5 month(s) ago
Between the years 2010 and 2017, 1.28 million cases of Non-Small Cell Lung Cancer (NSCLC) were reported in the United States [1]. With an estimated 1.8 million deaths per year, lung cancer is the leading cause of death from cancer [2]. Brain metastases are a common sequelae of lung cancer with up to 20 % of patients having brain metastases (BM) at presentation [3].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13One mutation to rule them all: Mutant KRAS controls tumor intrinsic and microenvironment signaling. - 5 month(s) ago
Abstract. In a recent study published in Cancer Discovery, Hsu and colleagues employ an elegant combination of single-cell and bulk RNA-seq experiments from mouse and human colorectal cancer (CRC) samples, patient-derived organoids, 2D in vitro systems, and in vivo validation in genetically engineered CRC mouse models to investigate how mutant KRAS (KRAS*) impacts the tumor microenvironment. They identify a molecular signaling cascade downstream of KRAS* that activates a specific program of lipid-rich CAFs, promoting tumor angiogenesis and progression. These findings may lead to new therapeutic strategies for CRC patients with KRAS*.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11Allosteric Regulation of Switch-II Domain Controls KRAS Oncogenicity - 7 month(s) ago
An allosteric network formed by interaction between lysine 104 and residues in the switch-II domain is required for KRAS oncogenicity, which could be exploited for developing inhibitors of the activated oncoprotein.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 17Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS - 7 month(s) ago
Small molecules recruit cyclophilin A to the active state of mutant KRAS to disrupt oncogenic signaling and tumor growth.
Source: www.science.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Original Article from The New England Journal of Medicine — Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Source: www.nejm.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Allosteric Regulation of Switch-II Domain Controls KRAS Oncogenicity - 7 month(s) ago
An allosteric network formed by interaction between lysine 104 and residues in the switch-II domain is required for KRAS oncogenicity, which could be exploited for developing inhibitors of the activated oncoprotein.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Regulatory update on sotorasib for #KRAS G12C NSCLC. FDA review of NDA complete and based on CodeBreak 200, issued a new postmarketing requirement for an additional confirmatory study to be completed by Feb 2028. Also confirmed the 960mg qday dose. https://t.co/ehNa5cBGVC